Predictors of Recurrence for High Risk Endometrial Cancer Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04412902

Enrollment

Registered

2020-06-02

Start date

2020-04-25

Completion date

2020-11-25

Last updated

2020-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

High-risk Endometrial Cancer

Brief summary

This study will analyze whether there is any difference in recurrence and survival rates among the patients who received different adjuvant therapies.

Detailed description

The incidence of endometrial cancer is gradually increasing nowaday. The postoperative treatment of high-risk endometrial cancer is also inconsistent. Besides, the recurrence of high-risk endometrial cancer is high.The investigators retrospective study will analyze the factors associated with recurrence of endometrial cancer, especially for different adjuvant therapies.

Interventions

DRUGadjuvant therapy

Adjuvant chemotherapy and/or radiotherapy

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* All patients with high risk stage I endometrial cancer and all patients with stage II and stage III endometrial cancer and who underwent therapy in Far Eastern Memorial Hospital from 2009/01/01\ 2019/09/17.

Exclusion criteria

* Patients with stage I endometrial cancer do not have high risk factors.

Design outcomes

Primary

Measure	Time frame	Description
Factors affecting overall survival	10 years	Factors affecting overall survival

Secondary

Measure	Time frame	Description
Factors affecting progression-free survival	10 years	Factors affecting progression-free survival

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026